VYNE Therapeutics's Return On Capital Employed Insights By: Benzinga via Benzinga March 18, 2022 at 10:09 AM EDT According to data from Benzinga Pro, during Q4, VYNE Therapeutics's (NASDAQ:VYNE) reported sales totaled $2.29 million. Despite a 45.64% ... Read More >> Related Stocks: Vyne Therapeutics Inc